Mutuiri Anderson P, Nzioka Ancent, Busarla Satya V P, Sayed Shahin, Moloo Zahir
Department of Pathology (A.P.M., S.S., Z.M.), Aga Khan University Hospital Department of Pathology (A.N.), Kenyatta University, Nairobi Department of Pathology (S.V.P.B.), Aga Khan Hospital, Kisumu, Kenya.
Int J Gynecol Pathol. 2016 Nov;35(6):537-543. doi: 10.1097/PGP.0000000000000272.
Ovarian carcinomas are a leading cause of cancer mortality among women. Two of the more commonly described markers of prognostic significance in primary ovarian carcinomas are p53 and HER2/neu. Overexpression of both markers is associated with poor prognosis. This study aimed to determine the frequency and pattern of p53 and HER2/neu expression in primary ovarian carcinomas in Kenyan women and to describe the clinical and pathologic features of ovarian carcinomas diagnosed at 3 different hospitals in Kenya. Primary ovarian carcinomas diagnosed at the Departments of Pathology at Aga Khan University Hospital, Nairobi; the Aga Khan Hospital, Kisumu; and the AIC Kijabe Hospital in Kenya over a period of 3 years from January 2009 to December 2011 were recorded. Sixty-seven ovarian carcinomas were identified and blocks retrieved from archives. Hematoxylin-eosin-stained slides of these were reviewed and appropriate sections were stained for p53 and HER2/neu using standard immunohistochemical techniques. The primary outcome was presence and intensity of staining for p53 and HER2/neu. The most frequent malignancy was serous carcinoma. A total of 43.3% (95% confidence interval, 32.1%-55.2%) of carcinomas were positive for p53, and 13.4% (95% confidence interval, 7.2%-23.6%) were positive for HER2/neu. Serous carcinoma and adenocarcinoma, not otherwise specified were more likely to be positive for p53. There was no association noted between the histologic grade or pathologic stage and positivity for either p53 or HER2/neu. The expression of p53 and HER2/neu in primary ovarian carcinomas in Kenyan women is not different from that described in the literature.
卵巢癌是女性癌症死亡的主要原因。在原发性卵巢癌中，两种较常描述的具有预后意义的标志物是p53和HER2/neu。两种标志物的过表达均与预后不良相关。本研究旨在确定肯尼亚女性原发性卵巢癌中p53和HER2/neu表达的频率和模式，并描述在肯尼亚3家不同医院诊断出的卵巢癌的临床和病理特征。记录了2009年1月至2011年12月期间在内罗毕阿迦汗大学医院病理科、基苏木阿迦汗医院以及肯尼亚AIC基贾贝医院诊断出的原发性卵巢癌。共识别出67例卵巢癌，并从档案中检索出组织块。对这些组织块的苏木精-伊红染色切片进行复查，并使用标准免疫组织化学技术对适当切片进行p53和HER2/neu染色。主要观察指标是p53和HER2/neu染色的存在情况和强度。最常见的恶性肿瘤是浆液性癌。共有43.3%（95%置信区间，32.1%-55.2%）的癌组织p53呈阳性，13.4%（95%置信区间，7.2%-23.6%）的癌组织HER2/neu呈阳性。浆液性癌和未另行特指的腺癌更有可能p53呈阳性。未观察到组织学分级或病理分期与p53或HER2/neu阳性之间存在关联。肯尼亚女性原发性卵巢癌中p53和HER2/neu的表达与文献中描述的无异。
